Healthcare
Live Price
Offline$451.63
-1.60% today
1Y Change
+1.82%
Window
Jun 23, 2025 → Jun 18, 2026
Coverage: 249 bars · Jun 23, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Vertex Pharmaceuticals Incorporated (VRTX) is a Healthcare stock with a market cap of $109.34B and listed on NASDAQ. The stock last traded around $451.63 and up 1.8% across the available one-year price window (Jun 23, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of +9.6%, EPS growth of +843.3%, a dividend yield of 0.0%. What stands out right now is revenue +9.6%, EPS +843.3%, free cash flow +504.1% with operating margin 35.5% and ROIC 16.2%. Valuation already assumes a fairly strong business story at P/E 27.6 and price/sales 9.1. Overall, the current profile looks closer to a quality compounder than a generic broad-market placeholder. Stock Foundry combines VRTX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
VRTX
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
VRTX Max Drawdown
-23.56%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for VRTX and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$7.6B
-15.2% YoY
FY Net Income
$2.3B
-29.5% YoY
Free Cash Flow
$2.4B
-38.6% YoY
Revenue Growth
+9.6%
EPS Growth
+843.3%
Gross Margin
86.3%
Net Margin
32.8%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 12.1B | 11.0B | 9.9B | 8.9B | 7.6B |
| Gross Profit | 10.3B | 9.5B | 8.6B | 7.9B | 6.7B |
| Operating Income | 4.8B | -233M | 3.8B | 4.3B | 2.8B |
| EBITDA | 5.0B | 486M | 4.6B | 4.4B | 2.9B |
| Net Income | 4.0B | -536M | 3.6B | 3.3B | 2.3B |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 5.1B | 4.6B | 10.4B | 10.5B | 6.8B |
| Total Assets | 26.1B | 22.5B | 22.7B | 18.2B | 13.4B |
| Total Liabilities | 7.5B | 6.1B | 5.1B | 4.2B | 3.3B |
| Shareholder Equity | 18.7B | 16.4B | 17.6B | 13.9B | 10.1B |
| Total Debt | 3.9B | 1.7B | 808M | 900M | 967M |
| Net Debt | -1.2B | -2.8B | -9.6B | -9.6B | -5.8B |
Cash flow positioning
Latest Full Year
Operating Cash Flow
2.6B
-36.0% YoY
Capital Expenditures
235M
-14.8% YoY
Free Cash Flow
2.4B
-38.6% YoY
Key ratios
Gross Margin
86.3%
Operating Margin
35.5%
Net Margin
32.8%
ROE
22.7%
Debt / Equity
0.21x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.